Cantor Fitzgerald reiterated its Overweight rating and $6.00 price target for Nyxoah SA on September 4, 2026. The affirmation follows the company's announcement on September 2nd that its ACCCESS U.S. pivotal study for the Genio system, a treatment for Obstructive Sleep Apnea (OSA), met its primary safety and efficacy endpoints.
The successful trial results, which showed a 77.2% responder rate and no device-related serious adverse events, are a crucial step for the company. Nyxoah is now on track to submit for Premarket Approval (PMA) with the FDA in late Q3 or early Q4 2026, potentially expanding its U.S. market indication to include patients with Complete Concentric Collapse (CCC). The positive news had already caused the stock to surge on September 3rd. Additionally, a lock-up agreement for certain company warrants was scheduled to end on September 4, 2026.